EGFR and head and neck squamous cell carcinoma: Our study is the first to demonstrate PI3K‐C2α acts as a driver of EGFR inhibitor resistance in HNSCC, as reducing PIK3C2A transcript levels led to growth inhibition and increased sensitivity to the EGFR inhibitor gefitinib, especially in long‐term culture models.